Home > Dermatology > SPIN 2022 > Where Are We Now in Hidradenitis Suppurativa > New treatments for HS: IL-17 inhibitors next in practice?

New treatments for HS: IL-17 inhibitors next in practice?

Presented By
Dr Axel Villani, University of Lyon, France & Prof. Thrasyvoulos Tzellos, Nordland Hospital Trust, Norway
Conference
SPIN 2022
Doi
https://doi.org/10.55788/315075e2
More therapy options are still lacking to manage most patients with hidradenitis suppurativa (HS) effectively. The next agents that approach approval will likely be IL-17 inhibitors. “We have some kind of explosion of new studies in HS: around 140 studies are registered in clinical trials, and approximately half of them concern phase 1, 2, or 3,” Dr Axel Villani (University of Lyon, France) said in his opening remarks on pipeline treatments [1]. Many of the different agents tested in HS can already be found in trials on psoriasis. “HS and psoriasis share some similarities in terms of molecular signature and inflammation, but they are not exactly the same,” Dr Villani pointed out. Among the manifold possible treatment targets influencing the immune response in HS are IL-1, IL-17, IL-23, IL-36, and B-cells. Research on IL-1 includes 2 small studies on MABp1 (NCT0264365...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on